Analysts expect that Alkermes Plc (NASDAQ:ALKS) will announce sales of $221.82 million for the current fiscal quarter, according to Zacks Investment Research. Two analysts have provided estimates for Alkermes’ earnings, with the lowest sales estimate coming in at $214.94 million and the highest estimate coming in at $228.70 million. Alkermes reported sales of $191.78 million during the same quarter last year, which indicates a positive year-over-year growth rate of 15.7%. The business is expected to report its next quarterly earnings report on Thursday, April 26th.

On average, analysts expect that Alkermes will report full year sales of $221.82 million for the current financial year, with estimates ranging from $987.90 million to $1.02 billion. For the next year, analysts expect that the business will report sales of $1.15 billion per share, with estimates ranging from $990.20 million to $1.24 billion. Zacks’ sales calculations are an average based on a survey of research firms that that provide coverage for Alkermes.

How to Become a New Pot Stock Millionaire

Alkermes (NASDAQ:ALKS) last issued its quarterly earnings data on Wednesday, February 14th. The company reported $0.31 earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.01) by $0.32. The firm had revenue of $275.37 million during the quarter, compared to analyst estimates of $251.23 million. Alkermes had a negative return on equity of 4.32% and a negative net margin of 17.48%. The business’s quarterly revenue was up 29.0% compared to the same quarter last year. During the same quarter last year, the business posted $0.02 earnings per share.

A number of brokerages have recently weighed in on ALKS. Morgan Stanley restated an “equal weight” rating and set a $67.00 price objective (up previously from $60.00) on shares of Alkermes in a research report on Friday, February 23rd. Jefferies Group lowered Alkermes from a “buy” rating to a “hold” rating and lifted their price target for the stock from $63.19 to $66.00 in a research report on Thursday, February 22nd. Cantor Fitzgerald reiterated a “hold” rating and issued a $50.00 price target on shares of Alkermes in a research report on Tuesday, February 20th. Credit Suisse Group lifted their price target on Alkermes from $66.00 to $70.00 and gave the stock an “outperform” rating in a research report on Friday, February 16th. Finally, Citigroup set a $62.00 price target on Alkermes and gave the stock a “hold” rating in a research report on Thursday, February 15th. Nine investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company. The stock currently has an average rating of “Hold” and an average target price of $64.58.

Shares of Alkermes stock traded down $0.38 during trading on Tuesday, hitting $61.25. The stock had a trading volume of 1,120,167 shares, compared to its average volume of 1,086,652. The stock has a market capitalization of $9,433.05, a price-to-earnings ratio of -59.47 and a beta of 1.87. The company has a current ratio of 2.78, a quick ratio of 2.46 and a debt-to-equity ratio of 0.23. Alkermes has a 52-week low of $46.42 and a 52-week high of $71.22.

In related news, Director Paul J. Mitchell sold 1,000 shares of Alkermes stock in a transaction dated Thursday, March 1st. The stock was sold at an average price of $57.04, for a total value of $57,040.00. Following the completion of the transaction, the director now owns 9,000 shares in the company, valued at $513,360. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, SVP Iain Michael Brown sold 10,652 shares of the firm’s stock in a transaction dated Friday, December 29th. The stock was sold at an average price of $54.81, for a total transaction of $583,836.12. The disclosure for this sale can be found here. In the last quarter, insiders sold 125,433 shares of company stock valued at $7,942,327. 5.34% of the stock is currently owned by company insiders.

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. The Manufacturers Life Insurance Company lifted its stake in Alkermes by 7.6% in the second quarter. The Manufacturers Life Insurance Company now owns 5,804 shares of the company’s stock worth $336,000 after purchasing an additional 409 shares during the last quarter. CIBC Asset Management Inc lifted its stake in Alkermes by 12.6% in the fourth quarter. CIBC Asset Management Inc now owns 7,287 shares of the company’s stock worth $399,000 after purchasing an additional 818 shares during the last quarter. Public Employees Retirement Association of Colorado lifted its stake in Alkermes by 3.2% in the fourth quarter. Public Employees Retirement Association of Colorado now owns 31,504 shares of the company’s stock worth $1,724,000 after purchasing an additional 970 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in Alkermes by 4.4% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 34,855 shares of the company’s stock worth $1,908,000 after purchasing an additional 1,462 shares during the last quarter. Finally, Dimensional Fund Advisors LP lifted its stake in Alkermes by 0.8% in the second quarter. Dimensional Fund Advisors LP now owns 196,108 shares of the company’s stock worth $11,369,000 after purchasing an additional 1,577 shares during the last quarter.

TRADEMARK VIOLATION NOTICE: This report was posted by Watch List News and is owned by of Watch List News. If you are reading this report on another publication, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The original version of this report can be viewed at https://www.watchlistnews.com/alkermes-plc-alks-expected-to-announce-quarterly-sales-of-221-82-million/1944060.html.

About Alkermes

Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS).

Get a free copy of the Zacks research report on Alkermes (ALKS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Alkermes (NASDAQ:ALKS)

Receive News & Ratings for Alkermes Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes and related companies with MarketBeat.com's FREE daily email newsletter.